Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.
Authors
- Oladapo Yeku (ORCID: https://orcid.org/0000-0002-6319-1647)
- Shivaani Kummar (ORCID: https://orcid.org/0000-0001-6906-1627)
- Winston Tan (ORCID: https://orcid.org/0000-0003-4706-0310)
- Judy Wang (ORCID: https://orcid.org/0000-0002-7355-7542)
- Minal Barve (ORCID: https://orcid.org/0009-0007-4259-7457)
- Joleen M. Hubbard (ORCID: https://orcid.org/0000-0001-8250-4920)
- Marc Charles Chamberlain (ORCID: https://orcid.org/0000-0002-1613-1123)
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- Ira Winer (ORCID: https://orcid.org/0000-0001-6056-8296)
- Sarah Lynam (ORCID: https://orcid.org/0000-0003-1474-6527)
- Siqing Fu (ORCID: https://orcid.org/0000-0002-1933-0419)
- Christos E. Kyriakopoulos (ORCID: https://orcid.org/0000-0002-6452-7405)
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
- Michael S. Gordon (ORCID: https://orcid.org/0000-0002-7679-9504)
- Amita Patnaik (ORCID: https://orcid.org/0000-0002-4144-2193)
- Abdul Rafeh Naqash (ORCID: https://orcid.org/0000-0001-7622-720X)
- Debra L. Richardson (ORCID: https://orcid.org/0000-0002-3992-8610)
Institutions
- University of Wisconsin System (US)
- Allina Health (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- Sarah Cannon Research Institute (GB)
- Wayne State University (US)
- Jacksonville College (US)
- Yale Cancer Center (US)
- Yale University (US)
- Mary Crowley Cancer Research Center (US)
- Massachusetts General Hospital (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Sarah Cannon (US)
- OSE Immunotherapeutics (France) (FR)
- South Texas Accelerated Research Therapeutics (US)
- University Hospitals Seidman Cancer Center (US)
- HonorHealth (US)
- Oklahoma State University Oklahoma City (US)
- Mayo Clinic in Florida (US)
- Center for Cancer Research (US)
- University of Oklahoma Health Sciences Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-010959
- Citations
- 10
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 7.97
Funders
- U.S. Department of Defense
- Conquer Cancer Foundation
- Amgen
- Pfizer
- AstraZeneca
- Gilead Sciences
- American Society of Clinical Oncology
- Endocyte
- Taiho Pharmaceutical
- Society for Immunotherapy of Cancer
- Celldex Therapeutics
- Hope Foundation
- Mersana Therapeutics
- BeiGene
- Incyte
- Syndax Pharmaceuticals
- Silverback Therapeutics
- G1 Therapeutics
- Seagen
- Springworks Therapeutics
- Y-mAbs Therapeutics
- Eisai
- Astellas Pharma
- Ministry of Minority Affairs
- Genentech
- Foundation Medicine
- Daiichi Sankyo Europe